Serum fibroblast growth factor 19 (FGF19) levels are associated with atherogenic dyslipidemia in patients with type 2 diabetes

Serum fibroblast growth factor 19 (FGF19) levels are associated with atherogenic dyslipidemia in patients with type 2 diabetes

Bibliographic Details
Main Authors:	Jing-Yi Hu, Hai-Lan Zou, Yan-Hua Li, Dong-Ying Nie, Chen Chao, Jin-Han Liu, Jin Ding, Zhi-Guang Zhou, Yang Xiao, Ning-Ning Wang
Format:	Article
Language:	English
Published:	Wolters Kluwer 2021-09-01
Series:	Chinese Medical Journal
Online Access:	http://journals.lww.com/10.1097/CM9.0000000000001574

Similar Items

Atherogenic dyslipidemia
by: C N Manjunath, et al.
Published: (2013-01-01)

Association of serum retinol binding protein 4 with atherogenic dyslipidemia in morbid obese patients.
by: Milagros Rocha, et al.
Published: (2013-01-01)

Correction: Association of Serum Retinol Binding Protein 4 with Atherogenic Dyslipidemia in Morbid Obese Patients
by: Milagros Rocha, et al.
Published: (2013-01-01)

Correction: Association of Serum Retinol Binding Protein 4 with Atherogenic Dyslipidemia in Morbid Obese Patients.
by: Milagros Rocha, et al.
Published: (2013-01-01)

Hibernating brown bears are protected against atherogenic dyslipidemia
by: Sylvain Giroud, et al.
Published: (2021-09-01)

Pathophysiological rationale for the results of atherogenic dyslipidemia simulation in rats
by: V. G. Banzaraksheev
Published: (2016-05-01)

Atherogenic Dyslipidemia and Cardiovascular Risk Factors in Obese Children
by: Ebe D’Adamo, et al.
Published: (2015-01-01)

Treatment of atherogenic dyslipidemia: modern principles and new possibilities
by: M. G Bubnova
Published: (2017-06-01)

Atherogenic dyslipidemia in children: evaluation of clinical, biochemical and genetic aspects.
by: Anna Montali, et al.
Published: (2015-01-01)

Modern principles of atherogenic dyslipidemia management in special groups of patients
by: Marina G. Bubnova, et al.
Published: (2020-09-01)

Cross-sectional study of pattern of Dyslipidemia and Prevalence of Atherogenic Diabetic Dyslipidemia in newly detected Diabetic patients
by: Vinay Krishnamurthy, et al.
Published: (2019-10-01)

Role of Glitazars in atherogenic dyslipidemia and diabetes: Two birds with one stone?
by: Srinivasa P Munigoti, et al.
Published: (2014-01-01)

The nuances of atherogenic dyslipidemia in diabetes: Focus on triglycerides and current management strategies
by: P.C. Manoria, et al.
Published: (2013-12-01)

The potential influence of atherogenic dyslipidemia on the severity of chronic Chagas heart disease
by: Luz Peverengo, et al.
Published: (2016-02-01)

Correction: Atherogenic Dyslipidemia in Children: Evaluation of Clinical, Biochemical and Genetic Aspects.
by: Anna Montali, et al.
Published: (2015-01-01)

Association of serum fibroblast growth factor 19 levels with arteriosclerosis parameters assessed by arterial stiffness and atherogenic index of plasma in patients with type 2 diabetes
by: Wang-shu Liu, et al.
Published: (2020-05-01)

FGF19 and FGF21: In NASH we trust
by: Saswata Talukdar, et al.
Published: (2021-04-01)

DYSLIPIDEMIA IN TYPE 2 DIABETES MELLITUS: MORE ATHEROGENIC LIPID PROFILE IN WOMEN
by: M. Nakhjavani, et al.
Published: (2006-04-01)

DYSLIPIDEMIA IN TYPE 2 DIABETES MELLITUS: MORE ATHEROGENIC LIPID PROFILE IN WOMEN
by: M. Nakhjavani, et al.
Published: (2006-06-01)

New atherogenic indices: Assessment of cardio vascular risk in post menopausal dyslipidemia
by: Pusapati Madan Ranjit
Published: (2015-05-01)

Cardiovascular risk profile of patients with atherogenic dyslipidemia in middle age Lithuanian population
by: Sandra Kutkiene, et al.
Published: (2018-09-01)

Atherogenic dyslipidemia and diabetes mellitus: what&rsquo;s new in the management arena?
by: Ajoy Kumar, et al.
Published: (2010-07-01)

Low carbohydrate diets improve atherogenic dyslipidemia even in the absence of weight loss
by: Volek Jeff S, et al.
Published: (2006-06-01)

Investigation into the mechanism and treatment of atherogenic dyslipidemia in HIV + patients with HIV metabolic syndrome
by: Green, Thomas James
Published: (2009)

Investigation into the mechanism and treatment of atherogenic dyslipidemia in HIV + patients with HIV metabolic syndrome
by: Green, Thomas James
Published: (2009)

Plasma fatty acid binding protein 4 is associated with atherogenic dyslipidemia in diabetes
by: Anna Cabré, et al.
Published: (2008-08-01)

Reduced HDL particle size as an additional feature of the atherogenic dyslipidemia of abdominal obesity
by: Agnès Pascot, et al.
Published: (2001-12-01)

Fundamentals of FGF19 & FGF21 action in vitro and in vivo.
by: Andrew C Adams, et al.
Published: (2012-01-01)

FGF19 and FGF21 for the Treatment of NASH—Two Sides of the Same Coin? Differential and Overlapping Effects of FGF19 and FGF21 From Mice to Human
by: Emma Henriksson, et al.
Published: (2020-12-01)

Association of CETP Gene Variants with Atherogenic Dyslipidemia Among Thai Patients Treated with Statin
by: Srisawasdi P, et al.
Published: (2021-01-01)

Correction of atherogenic dyslipidemia with honey, pollen and bee bread in patients with different body mass
by: Valentina Ivanovna Kas'yanenko, et al.
Published: (2011-08-01)

Atherogenic dyslipidemia in metabolic syndrome and type 2 diabetes: therapeutic options beyond statins
by: Fisman Enrique Z, et al.
Published: (2006-09-01)

PCSK7 gene variation bridges atherogenic dyslipidemia with hepatic inflammation in NAFLD patients
by: Paola Dongiovanni, et al.
Published: (2019-06-01)

Exercise increases serum fibroblast growth factor 21 (FGF21) levels.
by: Daniel Cuevas-Ramos, et al.
Published: (2012-01-01)

Differential specificity of endocrine FGF19 and FGF21 to FGFR1 and FGFR4 in complex with KLB.
by: Chaofeng Yang, et al.
Published: (2012-01-01)

Plasma vitamin D and parathormone are associated with obesity and atherogenic dyslipidemia: a cross-sectional study
by: Guasch Alba, et al.
Published: (2012-12-01)

CODAP: A multidisciplinary consensus among Portuguese experts on the definition, detection and management of atherogenic dyslipidemia
by: Alberto Mello e Silva, et al.
Published: (2019-08-01)

LDL subclass lipidomics in atherogenic dyslipidemia: effect of statin therapy on bioactive lipids and dense LDL[S]
by: M. John Chapman, et al.
Published: (2020-06-01)

Multiple QTLs influencing triglyceride and HDL and total cholesterol levels identified in families with atherogenic dyslipidemia
by: Yi Yu, et al.
Published: (2005-10-01)

Naringin abrogates HIV-1 protease inhibitors-induced atherogenic dyslipidemia and oxidative stress in vivo
by: Sanelisiwe Nzuza, et al.
Published: (2019-01-01)